

1 **Usefulness of aortic valve calcification in patients with low flow aortic stenosis**

2

3 Nils Sofus Borg Mogensen, MD<sup>1,2,3</sup>, Jordi Sanchez Dahl MD, PhD, DMSc<sup>1,3</sup>, Mulham  
4 Ali, MD<sup>1</sup>, Mohamed-Salah Annabi, MD, MSc<sup>2</sup>, Amal Haujir, MD<sup>1,2</sup>, Andréanne Powers,  
5 MD<sup>2</sup>, Rasmus Carter-Storch, MD, PhD<sup>1,3</sup>, Jasmine Grenier-Delaney, MSc<sup>2</sup>, Jacob Eifer  
6 Møller, MD, PhD, DMSc<sup>1,4</sup>, Kristian Altern Øvrehus MD, PhD<sup>1</sup>, Philippe Pibarot  
7 DVM, PhD<sup>2</sup>, Marie-Annick Clavel DVM, PhD<sup>1,2</sup>

8

9

10 <sup>1</sup> Department of Cardiology, Odense University Hospital, Odense, Denmark.

11 <sup>2</sup> Institut Universitaire de Cardiologie et de Pneumologie de Québec (Québec Heart and  
12 Lung Institute), Laval University, Québec, Québec, Canada.

13 <sup>3</sup> Clinical Institute, University of Southern Denmark, Odense, Denmark.

14 <sup>4</sup> Department of Cardiology, Copenhagen University Hospital Rigshospitalet,  
15 Copenhagen, Denmark.

16

17 **Running title:** AVC in low flow AS

18

19 **Addresses for correspondence:**

20 Dr Marie-Annick Clavel, Institut universitaire de cardiologie et de pneumologie de  
21 Québec, 2725 Chemin Sainte-Foy, Québec city, Québec, Canada, G1V-4G5.

22 Telephone number: 418-656-8711 (ext. 2678)

23 E-mail address: Marie-Annick.Clavel@criucpq.ulaval.ca.

24

25 **Words count:** 4675

26

27 **Disclosure:**

28 Dr Clavel received funding from Edwards Lifesciences for CT core laboratory analyses  
29 and Research grant from Medtronic, Edwards Lifesciences and Pi-Cardia with no direct  
30 personal compensation. Dr Pibarot received funding from Edwards Lifesciences and

31 Medtronic for echocardiography core laboratory analyses with no direct personal  
32 compensation. The remaining authors have nothing to disclose.

33

34 **Source of Funding:**

35 This work was supported by research grants from Canadian Institutes for Health  
36 Research, the Institut de cardiologie et de Pneumologie de Québec, the Region of  
37 Southern Denmark and the University of Southern Denmark.

38

39 **ABSTRACT**

40 **Background:** Aortic valve calcification (AVC) has been shown to be a powerful  
41 assessment of aortic stenosis severity (AS) and predictor of adverse outcome. However,  
42 its accuracy in patients with low-flow AS has not yet been proven.

43 **Objectives:** To assess the predictive value of AVC in patients classical (CLF, i.e. low left  
44 ventricular ejection fraction [LVEF]) or paradoxical (PLF, i.e. low flow preserved LVEF)  
45 AS patients.

46 **Methods:** We prospectively include 641 patients, 319 (49.8%) with CLF-AS and 322  
47 (50.2%) with PLF-AS who underwent Doppler-echocardiography and multidetector  
48 computed tomography. AVCratio was calculated as AVC divided by the sex-specific  
49 AVC threshold for AS-severity; AVC score  $\geq 2,000$  AU in males, and  $\geq 1,200$  AU in  
50 females. The primary endpoint of the study was all-cause mortality regardless of  
51 treatment.

52 **Results:** During a median follow-up of 4.9 (4.3-5.9) years there were 265 deaths. After  
53 comprehensive adjustment, AVCratio was associated with all-cause mortality in CLF-AS  
54 (aHR=1.25 [1.01-1.56];  $p < 0.05$ ) and PLF-AS (aHR=1.51[1.14-2.00];  $p = 0.004$ ) patients.  
55 There was an interaction ( $p = 0.001$ ) between AVC and AS flow pattern (i.e. CLF vs. PLF)  
56 with regard to the prediction of mortality. The best AVCratio threshold to predict  
57 mortality was different in CLF-AS (AVCratio  $\geq 0.7$ ) and PLF-AS (AVCratio  $\geq 1$ ) patients.  
58 After comprehensive analysis, AVCratio as a dichotomic variable was associated with  
59 all-cause mortality in all groups ( $p \leq 0.001$ ). The addition of AVCratio to the models  
60 improved all model's predictive value (all net reclassification index  $> 18\%$ ; all  $p \leq 0.05$ ).

61 **Conclusion:** In patients with CLF or PLF AS, AVC is a major predictor of mortality.  
62 Thus, AVC should be used in low flow patients to stratify risk. Importantly, in patients  
63 with reduced LVEF, a non-severe AS (i.e. AVC 70% of severe) could be associated with  
64 reduce survival.

65

## 66 **Clinical Perspective**

67 What is new?

- 68 - Aortic valve calcification is a powerful predictor of outcome in patients with low  
69 ejection fraction aortic stenosis and in patients with low-flow despite normal ejection  
70 fraction aortic stenosis.
- 71 - In patient with low ejection fraction aortic stenosis, a non-severe calcification  
72 (AVCratio=0.7) is associated with increased mortality. An AVCratio of 0.7  
73 correspond to an AVC of 840AU in female patients and 1,400AU in male patients.

74 What are the clinical implications?

- 75 - AVC should be used in low ejection fraction and low flow patients to assess aortic  
76 stenosis severity and stratify risk.
- 77 - A severe AVC, in patient with low-flow preserved ejection fraction, could help in  
78 clinical decision making.
- 79 - A moderate-to-severe AVC (i.e. AVCratio>0.7), in patients with low ejection  
80 fraction, is detrimental and may be used to refine clinical decision making.

81

## 82 **Introduction**

83 Evaluation of aortic stenosis (AS) severity is the cornerstone of the management of  
84 patients with AS. Indeed, all the recommendations for intervention in the current  
85 guidelines<sup>1,2</sup> target patients with severe AS, except patients requiring non-aortic valve  
86 related open-heart surgery; in this case, intervention on moderate AS may be considered.  
87 Doppler-echocardiography is the gold standard to assess AS severity. When a peak aortic  
88 jet velocity  $\geq 4\text{m/s}$  or a mean gradient (MG)  $\geq 40\text{mmHg}$  coexists with an aortic valve area  
89 (AVA)  $\leq 1\text{cm}^2$  or an indexed AVA  $\leq 0.6\text{cm}^2/\text{m}^2$  the diagnosis of severe AS is  
90 straightforward<sup>3</sup>. However, in up to 40% of the patients with AS, these parameters are  
91 discordant with, most of the time, a low velocity/MG despite a small AVA<sup>4</sup>. This  
92 discordance is often associated with a low flow state that is defined by a decreased left  
93 ventricular ejection fraction (LVEF  $< 50\%$ ) in Classical Low Flow patients (CLF) or,  
94 when LVEF is preserved, by a low stroke volume index (SVI  $\leq 35\text{ml}/\text{m}^2$ ) in Paradoxical  
95 Low Flow patients (PLF)<sup>1</sup>. In CLF patients, a dobutamine stress echocardiography is  
96 recommended to assess the actual AS severity. However, this test is not always  
97 performed, and when performed, often not conclusive as many patients do not respond  
98 sufficiently to dobutamine to reach a normal flow<sup>5</sup>. Moreover, in patients with PLF,  
99 dobutamine stress echocardiography is not recommended<sup>1</sup>.

100 The measurement of aortic valve calcification (AVC) by multidetector computed  
101 tomography (MDCT)<sup>6</sup> is an alternative imaging modality to assess AS severity. Sex-  
102 specific thresholds have been proposed to identify severe AS<sup>7</sup> and extensively validated,  
103 especially against hard endpoints<sup>8-10</sup>, but mostly in patients with normal flow. In the

104 present study, we aimed to evaluate the impact of AVC in patients with CLF and PLF  
105 AS.

## 106 **Methods**

107 We included patients aged  $\geq 18$  years with CLF (i.e. LVEF $<50\%$ ) or PLF (i.e. SV $_i \leq 35$   
108 mL/m<sup>2</sup>) AS in prospective studies at Institut Universitaire de Cardiologie et de  
109 Pneumologie de Quebec, Canada and Odense University Hospital, Denmark. Patients  
110 underwent concomitant (within 3 months) Doppler-echocardiography and computed  
111 tomography evaluation. Studies were accepted by local ethic committees and patients  
112 signed a written consent to participate.

### 113 Clinical data

114 All clinical, echocardiographic and MDCT data were prospectively collected as part of  
115 research protocols. Baseline clinical data included age, sex, body surface area (BSA),  
116 NYHA functional class, diabetes, hypertension, atrial fibrillation, coronary artery disease  
117 (CAD), and chronic kidney disease. The date of the transthoracic echocardiographic  
118 examination was defined as the baseline visit.

### 119 Echocardiography

120 Patients underwent a comprehensive transthoracic echocardiographic examination using  
121 commercially available ultrasound systems in accordance with the American Society of  
122 Echocardiography guidelines<sup>3, 11</sup>. Doppler values were calculated as the average of three  
123 cardiac cycles for patients with sinus rhythm and five cycles for atrial fibrillation. Left  
124 ventricular (LV) outflow tract diameter was measured in the parasternal long-axis view in  
125 early systole at the insertion of aortic valve leaflets. AVA was calculated by quantitative

126 Doppler ultrasound using the continuity equation. Peak flow velocity across the valve  
127 was determined in the echocardiographic window where the highest velocity could be  
128 recorded using continuous wave Doppler. Mean transvalvular gradient was estimated  
129 using the modified Bernoulli equation. LVEF was determined by the Simpson biplane  
130 method. LV stroke volume was calculated using pulsed-wave Doppler as the product of  
131 the LV outflow area and LV outflow tract time velocity integral and indexed for BSA to  
132 provide SV<sub>i</sub>.

133 Patients with LVEF<50% were considered with CLF-AS irrespective of SV<sub>i</sub> and patients  
134 with LVEF≥50% and SV<sub>i</sub>≤35ml/m<sup>2</sup> were considered with PLF-AS.

### 135 Cardiac computer tomography

136 Patients underwent non-contrast MDCT scan with available scanner (SOMATOM Force,  
137 SOMATON Definition, Siemens Medical Solution, Germany, and BRILLANCE iCT,  
138 Philips, The Netherlands). Non-contrast-enhanced calcium scans were performed using a  
139 prospective ECG gated scan at 60-80% of the QRS complex and with a tube voltage of  
140 120 kV. The images were reconstructed with a slice thickness of 2.5- or 3-mm<sup>6</sup>.  
141 Radiation expose was typically 1 millisievert. All calcium scoring assessments were  
142 conducted using the same process, with dedicated software (Aquarius iNtuition, Tera  
143 Recon, Inc., Foster City, California or Syngo Via, Siemens Healthineers, Munich,  
144 Germany), by uniformly trained operators in a core laboratory (ValvulaR Multi-Modality  
145 Imaging Core Laboratory (VarMI-CL) Quebec). AVC score was assessed by Agatston  
146 method, expressed in arbitrary units (AU)<sup>12, 13</sup>. AVCratio was calculated as AVC divided  
147 by the sex-specific AVC threshold for AS-severity; AVC score ≥2,000 AU in males, and

148  $\geq 1,200$  AU in females<sup>7, 8</sup>. Thus, an AVCratio  $\geq 1$  define a severe AS in both female and  
149 male patients.

### 150 Endpoints

151 The primary endpoint of the study was all-cause mortality regardless of treatment. The  
152 secondary end-point was all-cause mortality in patients who did not receive AVR.

### 153 Statistical analysis

154 Continuous variables were tested for normality with the Shapiro-Wilk test, the normally  
155 distributed variables are presented as mean  $\pm$ SD and compared between groups using  
156 Student's t-test. As AVC was not normally distributed, it is presented as median  
157 (interquartile range) and compared between groups using the Kruskal-Wallis test.  
158 Categorical variables are presented as number (percentage) and compared using Chi-  
159 square or Fisher's exact tests, as appropriate. The best thresholds of AVCratio to predict  
160 mortality was assessed by a penalized spline curve in each low flow AS pattern (i.e. CLF  
161 and PLF). Survival rates were calculated using the Kaplan–Meier analysis, and univariate  
162 and multivariate Cox proportional hazard regression (presented as adjusted hazard ratio:  
163 aHR [95% confidence interval], p-value). All multivariate Cox model were adjusted for  
164 the background model including age, sex, diabetes, hypertension, coronary artery disease,  
165 renal failure, atrial fibrillation, New York Heart Association functional class, LVEF, and  
166 AVR (as a dependent variable). Variables used in the background model were the  
167 clinically relevant variables as well as variables significantly associated with mortality in  
168 univariate analysis. To assess the additive value of AVCratio over the background model,  
169 net reclassification index (NRI) was used.



170 All statistical analyses were performed with STATA/SE V.17.0 (StataCorp, Texas, USA)  
171 software. A p-value<0.05 was considered statistically significant.

## 172 **Results**

### 173 Study population

174 We included 641 patients, 319 (49.8%) with CLF-AS and 322 (50.2%) with PLF-AS  
175 (Figure 1). Mean age of the patients was 77.0 ±9.8 years and 429 (67%) were male.  
176 Patients with CLF-AS were older, more often male and had overall more comorbidities  
177 and more symptoms than patients with PLF-AS (Table 1). CLF-AS patients had similar  
178 AVA with lower SVi, MG and peak aortic jet velocity but higher AVC than PLF-AS  
179 patients.

180 As expected, CLF AS patients with higher AVCratio were older and had more severe AS  
181 compared to CLF AS patients with low AVCratio (Table 2). As well, PLF AS patients  
182 with higher AVCratio were older, more symptomatic and have more severe AS compared  
183 to PLF AS patients with low AVCratio (Table 2).

### 184 Impact of AVC on overall mortality

185 During a median follow-up of 4.9 (4.3-5.9) years there were 265 deaths. After adjustment  
186 by the background model AVCratio as a continuous variable (aHR=1.30 [1.09-1.54];  
187 p=0.003) was associated with all-cause mortality in the whole cohort, as well as in CLF-  
188 AS (aHR=1.25 [1.01-1.56]; p<0.05) and PLF-AS (aHR=1.51[1.14-2.00]; p=0.004)  
189 patients.

190 Compared to background models, the addition of AVCratio improved significantly the  
191 models' predictive value (Net reclassification index: Whole cohort: 19.6%;  $p=0.01$ ; CLF:  
192 18.9%;  $p=0.05$ ; PLF: 25.6%;  $p=0.03$ ). Interestingly, there was an interaction ( $p=0.001$ )  
193 between AVC and AS flow pattern (i.e. CLF vs. PLF) with regard to the prediction of  
194 mortality.

195 The best AVCratio threshold to predict mortality was different in CLF-AS  
196 ( $\text{AVCratio} \geq 0.7$ , i.e. an absolute AVC of 840 AU in female patients and 1,400AU in male  
197 patients) and PLF-AS ( $\text{AVCratio} \geq 1$ , i.e. an absolute AVC of 1,200 AU in female patients  
198 and 2,000AU in male patients, as to define severe AS) patients. After comprehensive  
199 analysis, AVCratio as a dichotomic variable was associated with all-cause mortality in  
200 the whole cohort ( $\text{aHR}=2.44$  [1.63-3.64];  $p<0.0001$ ), as well as in CLF-AS  
201 ( $\text{AVCratio} \geq 0.7$ :  $\text{aHR}=4.01$  [1.83-8.77];  $p=0.001$ ) and PLF-AS ( $\text{AVCratio} \geq 1$ :  
202  $\text{aHR}=2.08$ [1.21-3.59];  $p=0.008$ ) patients (Figure 2).

203 Compared to background models, the addition of AVCratio as a dichotomic variable  
204 improved significantly the models' predictive value (Net reclassification index: Whole  
205 cohort: 42.9%;  $p<0.0001$ ; CLF: 44.6;  $p=0.0002$ ; PLF: 40.7%;  $p=0.001$ ).

#### 206 *Impact of AVC on outcome of patients who did not undergo AVR*

207 Among the 181 patients who never underwent AVR (Figure 1), there were 93 deaths  
208 during a median follow-up of 2.7 (2.0-4.0) years. After comprehensive adjustment,  
209 AVCratio as a continuous variable ( $\text{aHR}=2.21$ [1.51-3.25];  $p<0.0001$ ) and AVCratio as a  
210 dichotomic variable ( $\text{aHR}=2.18$ [1.17-4.07];  $p=0.01$ ) were independently associated with  
211 increased mortality (Figure 3, Panel A). Accordingly, AVCratio was independently

212 associated with increased mortality in CLF-AS patients (AVCratio: aHR=1.90[1.13-  
213 3.21]; p=0.02; AVCratio $\geq$ 0.7: aHR=2.75[1.11-6.82]; p=0.03), and in PLF-AS patients  
214 (AVCratio: aHR=3.96[1.72-9.09]; p=0.001; AVCratio $\geq$ 1: aHR=2.80[1.03-7.64]; p=0.04).  
215 Compared to background models, the addition of AVCratio as continuous or dichotomic  
216 variables improved significantly the models' predictive value (whole cohort: NRI $>$  40%;  
217 p $\leq$ 0.004; CLF: NRI $>$ 65; p $\leq$ 0.001; PLF: NRI $>$ 40%; p $\leq$ 0.03).

## 218 **Discussion**

219 The main findings of this study were that AVC is associated with increased mortality in  
220 both CLF-AS and PLF-AS patients. Interestingly, the best threshold to assess increased  
221 mortality was lower (i.e. AVC $\geq$ 0.7) in CLF-AS patients than in PLF-AS patients (i.e.  
222 AVC $\geq$ 1). In all analyses, the addition of AVCratio improved the predictive value of the  
223 model.

224 Since the development of sex-specific thresholds to identify severe AS, AVC  
225 demonstrated a strong and steady association with elevated mortality in AS, which makes  
226 it an important marker of AS severity. Indeed, sex-specific thresholds were associated  
227 with severe AS as documented by concordant AVA and MG at echocardiography<sup>7, 9, 14</sup>  
228 (except in young bicuspid patients, especially women)<sup>15</sup>, but they also predict overall  
229 mortality<sup>8</sup> as well as mortality under medical management<sup>8</sup>, aortic valve replacement<sup>9, 10</sup>  
230 and rapid progression of AS<sup>10</sup>. The present study demonstrates that the association of  
231 AVC with increase mortality and mortality under medical management remains in  
232 patients with low flow, regardless of LVEF.

233 The strong association with outcome implies that AVC also may be used to determine AS  
234 severity and timing intervention in patients with discordant AS when LVEF and/or stroke  
235 volume are reduced.

236 Despite dobutamine stress echocardiography being the gold standard in CLF-AS patients,  
237 it may be contraindicated and/or unreliable in many of these patients. Moreover, we  
238 previously demonstrated that dobutamine stress echocardiography remains inconclusive  
239 in more than 30% of patients<sup>5</sup> when using the combination of MG at peak stress  $\geq 40$  mm  
240 Hg and AVA at peak stress  $< 1.0$  cm<sup>2</sup> as proposed in the current guidelines<sup>1,2</sup>. This low  
241 sensitivity for identifying true-severe AS is probably the reason why the guidelines  
242 criteria were not predictive of excess mortality<sup>16</sup>. To overcome this issue, we proposed  
243 the projected AVA at normal flow rate, in order to consider the patient-specific increase  
244 in flow during dobutamine infusion<sup>17,18</sup>. The projected AVA predicted was demonstrated  
245 to be more accurate to identify true-severe AS than guidelines criteria, and it predicted  
246 mortality in both CLF-AS and PLF-AS patients<sup>16,18-20</sup>. However, the calculation of this  
247 parameter may be prone to mistake and poorly reproducible, as it requires a steady state  
248 at peak dobutamine stress to have a velocity time integral in the aorta and in the LV  
249 outflow tract at the same stress. Unfortunately, this steady state may not always be  
250 achieved at peak stress. On the opposite, AVC is an easy, robust, and reproducible  
251 parameter. AVC is measurable in all patients despite calcification in the aorta, the  
252 coronary arteries, the mitral annulus or LV outflow tract, the presence of a pacemaker or  
253 atrial fibrillation<sup>7,9,21</sup>. All these points nevertheless have to be taken into consideration to  
254 ensure the realization of the best scan possible (atrial fibrillation, elevated heart rate and  
255 premature ventricular beats have to be considered at the time of scanning)<sup>6</sup> and the most

256 accurate evaluation of calcification in the aortic valve (exclusion of peripheric  
257 calcification).

258 Interestingly, the level of AVC that predicted increased mortality in CLF-AS patients was  
259 in the moderate range with an AVCratio  $\geq 0.7$ , which represent 70% of the severe  
260 threshold, i.e. 840 AU in female patients and 1,400 AU in male patients. This finding is  
261 consistent with previous studies that demonstrated that patients with low LVEF had an  
262 excess mortality with a non-severe AS (i.e. a projected AVA  $\leq 1.2\text{cm}^2$ )<sup>18, 19</sup> and that in  
263 these patients an early intervention could be beneficial<sup>22, 23</sup>. However, in patients with  
264 PLF-AS, the threshold to predict excess mortality is the same than the threshold for  
265 severity. Indeed, there is no study that shows that the pathophysiology of AS could be  
266 different according to flow status, thus the severity threshold of AVC to identify severe  
267 AS remains AVCratio  $\geq 1$  whether patients have normal flow, PLF or CLF. Thus, the  
268 ventricle of patients with PLF-AS seems to be able to tolerate AS up to its severe stage.  
269 At this point of severe AS, intervention should be performed if patients are symptomatic.

270 The finding that AVC impacts outcome differently depending on LVEF is paramount, as  
271 it demonstrates that even milder ranges of AS may affect outcome in patients with  
272 reduced LVEF. This thought provoking finding, questions the use of outcome data to  
273 determine AS severity in patients with reduced LVEF.

## 274 **Conclusion**

275 In this large series of patients with CLF or PLF AS, AVC demonstrates to be a major  
276 predictor of mortality. Thus, AVC should be used in low flow patients to assess AS

277 severity and stratify risk. Importantly, in patients with reduced LVEF, a non-severe AS  
278 could be associated with reduce survival in patients with more than 70% of severe AVC.  
279

280 **Table 1: Baseline characteristic of the patients according to flow pattern**

	<b>Whole Cohort</b>	<b>CLF</b>	<b>PLF</b>
	N=641	N=319	N=322
<b>Clinical data</b>			
Age, year	77.0 ±9.8	78.1 ±9.0	75.9 ±10.5
Male Sex	429 (67%)	241 (76%)	188 (58%)
Hypertension	539 (84%)	269 (84%)	270 (84%)
Diabetes	233 (36%)	123 (39%)	110 (34%)
Coronary arteries disease	404 (63%)	237 (74%)	167 (52%)
Atrial fibrillation	272 (42%)	151 (47%)	121 (38%)
Renal failure	220 (34%)	137 (43%)	83 (26%)
<b>NYHA functional Class</b>			
1	68 (10%)	27 (8%)	40 (12%)
2	331 (52%)	146 (46%)	185 (57%)
3	218 (34%)	128 (40%)	90 (28%)
4	24 (4%)	18 (6%)	6 (2%)
<b>Echocardiographic data</b>			
Peak aortic jet, m/s	3.66 ±0.77	3.56 ±0.71	3.75 ±0.80
Mean gradient, mmHg	33.3 ±15.1	31.5 ±13.7	35.0 ±16.2
Aortic valve area, cm <sup>2</sup>	0.70 ±0.21	0.70 ±0.22	0.69 ±0.21
Stroke volume index, ml/m <sup>2</sup>	29.2 ±6.0	28.5 ±7.5	29.9 ±3.8
LV Ejection Fraction, %	47 ±16	33 ±10	61 ±6
<b>MDCT data</b>			
<b>Aortic valve calcification (AU)</b>			
Female patients	1414 (962 – 2216)	1599 (1003-2486)	1363 (844-1970)
Male patients	2295 (1558-3222)	2377 (1643-3250)	2209 (1402-3166)
AVC ratio	1.16 (0.79-1.66)	1.20 (0.83-1.68)	1.12 (0.70-1.62)

281

282 AVC: aortic valve calcification; LV: left ventricular; NYHA: New York Heart

283 Association

284

285

**Table 2: Baseline characteristic of the patients AS flow pattern and AVC threshold**

	CLF			PLF		
	AVCratio <0.7	AVCratio ≥0.7	p-value	AVCratio <1	AVCratio ≥1	p-value
	N=47	N=272		N=136	N=186	
<b>Clinical data</b>						
Age, year	75.3 ±10.6	78.6 ±8.6	0.019	73.1 ±11.6	77.9 ±9.1	<0.001
Male Sex	38 (81%)	203 (75%)	0.36	80 (59%)	108 (58%)	0.89
Hypertension	39 (83%)	230 (85%)	0.78	114 (84%)	156 (84%)	0.99
Diabetes	20 (43%)	103 (38%)	0.54	57 (42%)	53 (28%)	0.01
Coronary arteries disease	33 (70%)	204 (75%)	0.49	62 (46%)	105 (56%)	0.05
Renal failure	23 (49%)	128 (47%)	0.81	49 (36%)	72 (39%)	0.62
Atrial fibrillation	20 (43%)	117 (43%)	0.95	30 (22%)	53 (28%)	0.19
NYHA functional class						
1	5 (11%)	22 (8%)	0.50	29 (21%)	12 (6%)	0.002
2	26 (55%)	120 (44%)		67 (49%)	118 (63%)	
3	14 (30%)	114 (42%)		37 (27%)	53 (28%)	
4	2 (4%)	16 (6%)		3 (2%)	3 (2%)	
<b>Echocardiographic data</b>						
Peak aortic jet, m/s	2.97 ±0.59	3.66 ±0.68	<0.001	3.36 ±0.60	4.04 ±0.82	<0.001
Mean gradient, mmHg	21.0 ±9.3	33.3 ±13.5	<0.001	26.8 ±10.9	41.1 ±16.9	<0.001
Aortic valve area, cm <sup>2</sup>	0.89 ±0.26	0.66 ±0.20	<0.001	0.79 ±0.22	0.62 ±0.16	<0.001
Stroke volume index, ml/m <sup>2</sup>	29.3 ±7.6	28.4 ±7.4	0.47	30.5 ±3.6	29.5 ±3.9	0.02
LV Ejection Fraction, %	36 ±10	32 ±10	0.035	61 ±6	61 ±7	0.75
<b>MDCT data</b>						



Aortic valve calcification, AU						
Women	719 (528-796)	1679 (1151-2671)	<0.001	759 (470-1009)	1843 (1494-2403)	<0.001
Men	1055 (767-1236)	2553 (1953-3362)	<0.001	1304 (903-1674)	2893 (2416-3841)	<0.001
AVC ratio	0.53 (0.38-0.63)	1.30 (0.97-1.71)	<0.001	0.65 (0.41-0.84)	1.51 (1.22-1.96)	<0.001

AVC: aortic valve calcification; LV: left ventricular; NYHA: New York Heart Association

## **Figure legend**

### **Figure 1: Flow chart of the study**

The figure shows the number of patients with low flow aortic stenosis (AS) included in the study, as well as the number of patients with decreased left ventricular ejection fraction (i.e. Classical Low Flow AS patients) and those with preserved left ventricular ejection fraction (i.e. Paradoxical Low Flow AS patients). In each subgroup, patients are divided according to management.

### **Figure 2: Cox-adjusted survival curves according to aortic valve calcification**

The figure shows the Cox-adjusted survival curves according to the elevation of aortic valve calcification (AVC) in the whole cohort (Panel A), Classical Low Flow Aortic Stenosis (CLF-AS) patients (Panel B) and Paradoxical Low Flow Aortic Stenosis (PLF-AS) patients (Panel C).

In CLF-AS patients AVC is considered elevated if  $AVC_{ratio} \geq 0.7$  (i.e. the ratio of measured AVC on the sex-specific threshold identifying severe AS: 1,200 in female patients and 2,000 in male patients). In PLF-AS patients AVC is considered elevated if  $AVC_{ratio} \geq 1$ .

### **Figure 3: Cox-adjusted survival curves according to aortic valve calcification in patients managed medically**

The figure shows the Cox-adjusted survival curves of AS patients who never underwent aortic valve replacement, according to the elevation of aortic valve calcification (AVC) in

the whole cohort (Panel A), Classical Low Flow Aortic Stenosis (CLF-AS) patients (Panel B) and Paradoxical Low Flow Aortic Stenosis (PLF-AS) patients (Panel C).

Figure 1




Figure 2 Panel A




Figure 2 Panel B




Figure 2 Panel C




Figure 3 Panel A






Figure 3 Panel B





Figure 3 Panel C



## References

1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, 3rd, Thompson A and Toly C. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines; executive summary. *Circulation*. 2021;143:e35-e71.
2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C and Wojakowski W. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2022;43:561-632.
3. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Hung B, Otto CM, Pellikka PA and Quinones M. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr*. 2009;22:1-23.
4. Clavel MA, Burwash IG and Pibarot P. Cardiac imaging for assessing low-gradient severe aortic stenosis. *JACC Cardiovasc Imaging*. 2017;10:185-202.
5. Mogensen NSB, Ali M, Carter-Storch R, Annabi MS, Grenier-Delaney J, Møller JE, Øvrehus KA, Pellikka P, Pibarot P, Clavel MA and Dahl J. Dobutamine Stress Echocardiography in Low-Gradient Aortic Stenosis. *Journal of the American society of echocardiography*. 2024.
6. Pawade T, Sheth T, Guzzetti E, Dweck MR and Clavel MA. Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis. *JACC Cardiovasc Imaging*. 2019;12:1835-1848.
7. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal S, Malouf J, Araoz P, Michelena H, Cuffe C, Larose É, Capoulade R, Vahanian A and Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: New insights from combined Doppler-echocardiographic and computed tomographic study. *J Am Coll Cardiol*. 2013;62:2329-2338.
8. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarwal S, Araoz PA, Michelena HI, Cuffe C, Larose É, Miller JD, Vahanian A and Enriquez-Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. *J Am Coll Cardiol*. 2014;64:1202-1213.
9. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Renard C, Gun M, Jenkins WSA, Macron L, Sechrist JW, Lacomis JM, Nguyen V, Galian Gay L, Cuellar Calabria H, Ntalas I, Carlidge TRG, Prendergast B, Rajani R, Evangelista A, Cavalcante JL, Newby DE, Pibarot P, Messika Zeitoun D and Dweck MR. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. *Circ Cardiovasc Imaging*. 2018;11:e007146.
10. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, Michelena HI, Larose É, Arsenault M, Bédard E, Pibarot P and Clavel MA. Impact of aortic valve calcification and sex on hemodynamic progression and clinical outcomes in AS. *J Am Coll Cardiol*. 2017;69:2096-2098.
11. Lang RM, Badano LP, Mor-Avi V, Afzalpoor A, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39.
12. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr. and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol*. 1990;15:827-832.

13. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cuffe C, Malouf J, Araoz PA, Mankad R, Michelena H, Vahanian A and Enriquez-Sarano M. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. *Circ Cardiovasc Imaging*. 2013;6:40-47.
14. Shen M, Guzzetti E, Oh JK, Singh GK, Pawade T, Tastet L, Clavel MA, Delgado V, Bax JJ, Dweck MR, Abbas AE, Mando R, Falconi ML, de Arenaza DP, Tay E, Pressman G, Brito D, Song JK and Pibarot P. Computed tomography aortic valve calcium scoring in patients with bicuspid aortic valve stenosis. *Structural Heart*. 2022;6:100027.
15. Shen M, Tastet L, Capoulade R, Larose É, Bédard É, Arsenault M, Chetaille P, Dumesnil JG, Mathieu P, Clavel MA and Pibarot P. Effect of age and aortic valve anatomy on calcification and haemodynamic severity of aortic stenosis. *Heart*. 2017;103:32-39.
16. Annabi MS, Touboul E, Dahou A, Burwash IA, Bergler-Klein J, Enriquez-Sarano M, Orwat S, Baumgartner H, Mascherbauer J, Mundigler G, Cavalcante JL, Larose É, Pibarot P and Clavel MA. Dobutamine stress echocardiography for management of low-flow, low-gradient aortic stenosis. *J Am Coll Cardiol*. 2018;71:475-85.
17. Blais C, Burwash IG, Mundigler G, Dumesnil JG, Loho N, Rader F, Baumgartner H, Beanlands RS, Chayer B, Kadem L, Garcia D, Durand LG and Pibarot P. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low flow, low-gradient aortic stenosis: The multicenter TOPAS (Truly or Pseudo Severe Aortic Stenosis) study. *Circulation*. 2006;113:711-721.
18. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, Sénéchal M, Mathieu P, Couture C, Beanlands R and Pibarot P. Validation of conventional and simplified methods to calculate projected valve area at normal flow rate in patients with low flow, low gradient aortic stenosis: the multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. *J Am Soc Echocardiogr*. 2010;23:380-386.
19. Clavel MA, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, Beanlands RS, Mathieu P, Magne J and Pibarot P. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. *Circulation*. 2008;118:S234-S242.
20. Clavel MA, Ennezat PV, Maréchaux S, Dumesnil JG, Capoulade R, Hachicha Z, Mathieu P, Bellouin A, Bergeron S, Meimoun P, Arsenault M, Le Tourneau T, Pasquet A, Couture C and Pibarot P. Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF. *J Am Coll Cardiol Img*. 2013;6:175-183.
21. Doris MK, Jenkins W, Robson P, Pawade T, Andrews JP, Bing R, Cartlidge T, Shah A, Pickering A, Williams MC, Fayad ZA, White A, van Beek EJ, Newby DE and Dweck MR. Computed tomography aortic valve calcium scoring for the assessment of aortic stenosis progression. *Heart*. 2020;106:1906-1913.
22. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, Vollema EM, El Azzouzi I, Spitzer E, Delgado V, Bax JJ and Clavel MA. Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol*. 2021;77:2796-803.
23. Ludwig S, Schofer N, Abdel-Wahab M, Urena M, Jean G, Renker M, Hamm CW, Thiele H, lung B, Ooms JF, Wiessman M, Mogensen NSB, Longère B, Perrin N, Ben Ali W, Coisne A, Dahl JS, Van Mieghem NM, Kornowski R, Kim WK and Clavel MA. Transcatheter aortic valve replacement in patients with reduced ejection fraction and nonsevere aortic stenosis. *Circ Cardiovasc Interv*. 2023;16:e012768.